## **Scholars Journal of Applied Medical Sciences**

Abbreviated Key Title: Sch J App Med Sci ISSN 2347-954X (Print) | ISSN 2320-6691 (Online) Journal homepage: <u>https://saspublishers.com</u>

Anaesthesiology

# The Outcome of Lignocaine HCL, and Labetalol HCL in Low Doses for Attenuation of Hemodynamic Response to Laryngoscopy and Intubation Dr. Sheikh Rukun Uddin Ahmed<sup>1\*</sup>

<sup>1</sup>MBBS, MCPS, DA (BSMMU), MD (Anaesthesiology); Senior Consultant (Anaesthesia & Intensive Care Unit), BBMH, USTC,

**DOI:** <u>10.36347/sjams.2022.v10i07.004</u>

| **Received:** 24.05.2022 | **Accepted:** 02.07.2022 | **Published:** 12.07.2022

\*Corresponding author: Dr. Sheikh Rukun Uddin Ahmed MBBS, MCPS, DA (BSMMU), MD (Anaesthesiology); Senior Consultant (Anaesthesia & Intensive Care Unit), BBMH, USTC, Foy's Lake, Chattogram

#### Abstract

Foy's Lake, Chattogram

**Original Research Article** 

**Background:** Recently lower dosages of lignocaine and labetalol have been proven to be beneficial in reducing perioperative adverse cardiovascular events. **Objective:** In this study our main goal is to evaluate the outcome of lignocaine HCL, and labetalol HCL in low doses for attenuation of hemodynamic response to laryngoscopy and intubation. **Method:** This prospective study was done at tertiary hospital from January 2020 to December 2021. In this study 100 consenting patients of age group 31–60 years of either sex and various general surgical procedures under endotracheal anesthesia were included in this study. During the study, 100 patients were randomly divided into two groups depending on the study drug to be given: Group LB: Injection labetalol HCL 0.25 mg/kg body weight diluted to 10 ml with 0.9% saline was given IV 5 min before intubation over 60 s, n=50 and Group LG: Injection lignocaine HCL 1 mg/kg body weight diluted to 10 ml with 0.9% saline was given IV 5 min before intubation over 60 % were male. The increase in mean HR was observed in LG groups but least in labetalol group. Besides that, increase in SBP in group lignocaine but not in labetalol group whereas DBP increased in all both groups almost similarly. RPP in peri-intubation period was most stable in group LB whereas mean atrial pressure increase in group LG was higher than that in group LB. **Conclusion:** Labetalol was found to be superior for the reduction of HR, SBP, DBP, mean arterial pressure, and RPP during and after laryngoscopy and endotracheal intubation in both intra- and inter-group comparisons.

Keywords: laryngoscopy, hemodynamic response, labetalol.

Copyright © 2022 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

#### **INTRODUCTION**

Direct laryngoscopy and endotracheal intubation typically result in a cardiovascular stress response seen as hypertension, tachycardia, and a rise in blood catecholamine levels. These reex hemodynamic alterations are easier tolerated in healthy people, but they are substantially amplified and harmful in comorbid individuals [1-4]. These hemodynamic stress reactions in vulnerable individuals can result in lifethreatening diseases such as left ventricular failure, myocardial ischemia, cerebral hemorrhage, and burst cerebral aneurysms, among others.

In this case, the use of intravenous (IV) lignocaine has yielded good results. The mechanism of IV local anesthetics appears to be caused by a higher threshold for airway stimulation and central suppression of sympathetic transmission. Increasing the dosage of lignocaine may cause hypotension, bradycardia, and

hypoxia. Whereas, labetalol, and a blocker, has also been proven to be beneficial in reducing perioperative adverse cardiovascular events, but greater dosages may produce hypotension and bradycardia [5, 6]. The argument for continuing the search for an optimum anesthetic approach that is both effective and safe in order to reduce adverse cardiovascular effects may be found here. Numerous attempts have been attempted to obstruct these unfavorable reexes via the usage of various measures and medications [7].

In this study our main goal is to evaluate the outcome of lignocaine HCL, and labetalol HCL in low doses for attenuation of hemodynamic response to laryngoscopy and intubation.

#### **OBJECTIVE**

To evaluate the efficacy of lignocaine HCL, and labetalol HCL in low doses for attenuation of hemodynamic response to laryngoscopy and intubation.

Citation: Sheikh Rukun Uddin Ahmed. The Outcome of Lignocaine HCL, and Labetalol HCL in Low Doses for Attenuation of Hemodynamic Response to Laryngoscopy and Intubation. Sch J App Med Sci, 2022 July 10(7): 1054-1057.

#### **METHODOLOGY**

This prospective study was done at tertiary hospital January 2020 to December 2021. In this study 100 consenting patients of age group 31–60 years of either sex or various general surgical procedures under endotracheal anesthesia were included in this study. During the study, 100 patients were randomly divided into two groups depending on the study drug to be given: Group LB: Injection labetalol HCL 0.25 mg/kg body weight diluted to 10 ml with 0.9% saline was given IV 5min before intubation over 60 s, n=50 and Group LG: Injection lignocaine HCL 1 mg/kg body weight diluted to 10 ml with 0.9% saline was given IV 5 min before intubation over 60 s, n=50.

#### RESULTS

In Table 1 shows age distribution where majority were belong to 41-50 years age group, 40% followed by 30% belong to 31-40 years age group, 20% belong to >51 years. The following table is given below in detail:

Table	1: Age	distribution

Age group	Percent
31-40 years	30
41-50 years	40
>51 years	20
Total	100.0

In figure 1 shows gender distribution of the patients where majority were male, 60%. The following figure is given below in detail:




Figure 1: Gender distribution of the patients

In Table 2 shows distribution of the patients according to heart rate where the increase in mean HR

was observed in LG groups but least in labetalol group. The following table is given below in detail:

Table 2. Distribution of the patients according to heart rate				
Heart rate	Group LB	Group LG	Group LB versus Group LG	
BV	98.52±8.53	98.84±11.95	0.90	
DL	103.4±8.73	111.6±9.40	0.00	
AI1	101.08±8.65	$111.04{\pm}10.74$	0.00	
AI3	96.68±8.43	108.4±10.70	0.00	
AI5	97.4±6.91	105.6±11.06	0.00	
AI7	96.48±7.10	103.16±8.85	0.00	
AI10	97.6±6.91	$100.24 \pm 8.70$	0.23	

In Table 3 shows Comparison of mean systolic blood and diastolic pressure between groups where increase in SBP in group lignocaine but not in labetalol

group whereas DBP increased in all both groups almost similarly. The following table is given below in detail:

Table 3: Comparison of mean systolic blood and diastolic pressure between groups					
Systolic Blood pressure	Group LB	Group LG	Group LB versus Group LG		
BV	122.76±7.76	122.16±7.06	0.00		
DL	127.72±9.41	138.92±12.26	0.00		
AI1	123.12±6.10	139.08±10.91	0.00		
AI3	121.72±6.52	136.04±11.76	0.00		
AI5	120.28±7.71	135±12.23	0.00		

© 2022 Scholars Journal of Applied Medical Sciences | Published by SAS Publishers, India

1055

AI7	121.08±8.23	134.6±13.19	0.00
AI10	120.08±9.78	133.72±10.86	0.00
Diastolic blood pressure	Group LB	Group LG	Group LB versus Group LG
BV	$78.88 \pm 2.94$	79.6±5.53	0.56
DL	87.16±8.28	94.32±12.13	0.01
AI1	85.16±5.94	91.76±13.09	0.03
AI3	84.32±7.15	89.65±11.75	0.06
AI5	$85.04 \pm 8.83$	89.36±12.29	0.17
AI7	86.00±7.76	88.56±12.87	0.41
AI10	83.6±10.22	87.36±11.65	0.24

Sheikh Rukun Uddin Ahmed; Sch J App Med Sci, July, 2022; 10(7): 1054-1057

In Table 4 shows comparison of mean arterial pressure among between two groups where increase in

group LG was higher than that in group LB. The following table is given below in detail:

Table 4: Comparison of mean arteria	l pressure among between two groups
-------------------------------------	-------------------------------------

Arterial pressure	Group LB	Group LG	Group LB versus Group LG
BV	93.507±3.67	93.786±5.27	0.83
DL	100.68±7.95	109.186±10.21	0.00
AI1	97.813±5.57	107.533±11.01	0.00
AI3	96.786±6.37	105.133±10.46	0.00
AI5	96.786±7.74	104.573±11.38	0.00
AI7	97.693±6.96	103.906±12.05	0.04
AI10	95.76±9.33	102.833±10.31	0.01

In Table 5 shows comparison of means rate pressure product (RPP) between two groups where RPP

in peri-intubation period was most stable in group LB. The following table is given below in detail:

Table 5: Comparison of means rate	pressure p	oroduct (RPP)	) between two groups
-----------------------------------	------------	---------------	----------------------

Means rate pressure product	Group LB	Group LG	Group LB versus Group LG
BV	12,092±259.17	12,103.20±1892.11	0.97
DL	13,204.20±274.88	15,563.36±2493.65	0.00
AI1	12,446.24±218.58	15,456.24±2143.28	0.00
AI3	11,759±268.12	14,748.16±2006.29	0.00
AI5	11,737.28±242.52	14,250.60±2013.00	0.00
AI7	11,685.68±242.52	13,904±1908.01	0.00
AI10	11,756.24±313.86	13,385.92±1439.73	0.00

### **DISCUSSION**

There was only slight and statistically insignificant increase in SBP in labetalol group at 1 min AI. Thereafter up to 10th min of intubation SBP was significantly lower than baseline values. Contrary to labetalol group in other two groups SBP was significantly higher at DL and intubation, and remained higher till 10th min of study period. Hence, comparison of labetalol with lignocaine, labetolol was found to be more efficacious than lignocaine in attenuating the SBP response to laryngoscopy and intubation.

Here labetalol is selective  $\alpha 1$  and nonselective  $\beta 1$  and  $\beta 2$  adrenergic receptor blocking agent, it lowers the systemic blood pressure by decreasing systemic vascular resistance ( $\alpha 1$  action) and also controls reeks tachycardia triggered by vasodilatation by  $\beta$  blockade. It also has weak  $\beta 2$  agonistic activity therefore may cause vasodilatation. Cardiac output remains unchanged [8-10].

Lignocaine practically has minimal hypotensive and no vasodilating properties [11]. Thus, the change in mean SBP was most effectively attenuated by labetalol, whereas lignocaine showed least attenuation effect among the study drugs.

In our study, the rise in DBP was not significantly attenuated (P < 0.05) by lignocaine, whereas labetalol showed statistically significant attenuation at least up to 3 min. The reason might be that our study drugs labetalol, and lignocaine are not very effective in controlling DBP rise. It is stated in the pharmacology of labetalol that "Increase in SBP rise during exercise are reduced by labetalol but corresponding changes in DBP are essentially normal [12].

Labetalol found to be more efficacious than esmolol in attenuating the mean arterial pressure response to laryngoscopy and intubation. However, this effect was not observed at DL and immediately thereafter. However, grossly the change in mean arterial pressure was most effectively attenuated by labetalol, , while lignocaine showed least attenuation effect among the study drugs.

Our results concurred with the study they found that lignocaine 1.5 mg/kg were not superior to each other in suppression of hemodynamic response to intubation [13].

RPP is an index of myocardial oxygen consumption. It is the product of SBP and HR. Values in excess of 15,000 are considered critical. Increase in RPP due to increase in HR is potentially more deleterious than that due to increase in blood pressure [14].

In our study, in group LB RPP never exceeded critical 15,000 marks. Thus the change in mean RPP was most effectively attenuated by labetalol, whereas lignocaine showed least attenuation effect among the study drugs.

In a recent study on comparison of labatelol with dexmedetomidine, dexmedetomidine better attenuated the sympathomimetic responses to endotracheal intubation. Although labetalol had maintained the stability of the blood pressure, HR response was not attenuated better DL and intubation [15].

#### CONCLUSION

Labetalol was found to be superior for the reduction of HR, SBP, DBP, mean arterial pressure, and RPP during and after laryngoscopy and endotracheal intubation in both intra- and inter-group comparisons.

#### **R**EFERENCES

- 1. Stoetling, R. K. (1977). Circulatory changes during direct laryngoscopy and tracheal intubation: influence of duration of laryngoscopy and tracheal intubation with or without prior lidocaine. *Anesthesiology*, *47*, 381-384.
- 2. Forbes, A. M., & Dally, F. G. (1970). Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. *BJA: British Journal of Anaesthesia*, 42(7), 618-624.
- King, B. D., Harris, L. C., Greifenstein, F. E., Elder, J. D., & Dripps, R. D. (1951). Reflex circulatory responses to direct laryngoscopy and tracheal intubation performed during general anesthesia. *The Journal of the American Society of Anesthesiologists*, 12(5), 556-566.
- Low, J. M., Harvey, J. T., Prys-Roberts, C., & Dagnino, J. (1986). Studies of anaesthesia in relation to hypertension: VII: Adrenergic responses

to laryngoscopy. British Journal of Anaesthesia, 58(5), 471-477.

- Prys-Roberts, C., Foex, P., Biro, G. P., & Roberts, J. G. (1973). Studies of anaesthesia in relation to hypertension V: adrenergic beta-receptor blockade. *British Journal of Anaesthesia*, 45(7), 671-681.
- 6. Yukioka, H., Yoshimoto, N., Nishimura, K., & Fujimori, M. (1985). Intravenous lidocaine as a suppressant of coughing during tracheal intubation. *Anesthesia and analgesia*, 64(12), 1189-1192.
- Laurito, C. E., Baughman, V. L., Becker, G. L., Polek, W. V., Riegler, F. X., & VadeBoncouer, T. R. (1988). Effects of aerosolized and/or intravenous lidocaine on hemodynamic responses to laryngoscopy and intubation in outpatients. *Anesthesia and analgesia*, 67(4), 389-392.
- Feng, C. K., Chan, K. H., Liu, K. N., Or, C. H., & Lee, T. Y. (1996). A comparison of lidocaine, fentanyl, and esmolol for attenuation of cardiovascular response to laryngoscopy and tracheal intubation. *Acta Anaesthesiologica Sinica*, 34(2), 61-67.
- Ramanathan, J., Sibai, B. M., Mabie, W. C., Chauhan, D., & Ruiz, A. G. (1988). The use of labetalol for attenuation of the hypertensive response to endotracheal incubation in preeclampsia. *American journal of obstetrics and* gynecology, 159(3), 650-654.
- 10. Inada, E., Cullen, D. J., Nemeskal, A. R., & Teplick, R. (1989). Effect of labetalol or lidocaine on the hemodynamic response to intubation: a controlled randomized double-blind study. *Journal of clinical anesthesia*, *1*(3), 207-213.
- 11. Chung, K. S., Sinatra, R. S., & Chung, J. H. (1992). The effect of an intermediate dose of labetalol on heart rate and blood pressure responses to laryngoscopy and intubation. *Journal of clinical Anesthesia*, 4(1), 11-15.
- Lee, H. Y., Yim, C. H., Chung, C. W., & Kim, H. Y. (1994). The Effect of Labetalol on the Hemodynamic Response to Endotracheal Intubation. *Korean Journal of Anesthesiology*, 27(11), 1611-1619.
- 13. Singh, S. P., Quadir, A., & Malhotra, P. (2010). Comparison of esmolol and labetalol, in low doses, for attenuation of sympathomimetic response to laryngoscopy and intubation. *Saudi journal of anaesthesia*, 4(3), 163-168.
- 14. Reid, L. C., & Brace, D. E. (1940). Irritation of the respiratory tract and its reflex effect upon heart. *Surg Gynecol Obstet*, *70*, 157-62.
- 15. TAKESHIMA, K., NODA, K., & HIGAKI, M. (1964). Cardiovascular response to rapid anesthesia induction and endotracheal intubation. *Anesthesia & Analgesia*, 43(2), 201-208.

© 2022 Scholars Journal of Applied Medical Sciences | Published by SAS Publishers, India